1. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol. 1969; 56:111–128. PMID:
5792556.
2. Stampfer MJ, Malinow MR. Can lowering homocysteine levels reduce cardiovascular risk? N Engl J Med. 1995; 332:328–329. PMID:
7654269.
Article
3. Arafa A, Lee HH, Eshak ES, et al. Modifiable risk factors for cardiovascular disease in Korea and Japan. Korean Circ J. 2021; 51:643–655. PMID:
34227266.
Article
4. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med. 1998; 338:1042–1050. PMID:
9535670.
Article
5. Bowden J, Holmes MV. Meta-analysis and Mendelian randomization: a review. Res Synth Methods. 2019; 10:486–496. PMID:
30861319.
6. Choi CK, Kweon SS, Lee YH, et al. Association between plasma homocysteine level and mortality: a Mendelian randomization study. Korean Circ J. 2023; 53:710–719. PMID:
37559417.
Article
7. Fan R, Zhang A, Zhong F. Association between homocysteine levels and all-cause mortality: a dose-response meta-analysis of prospective Studies. Sci Rep. 2017; 7:4769. PMID:
28684797.
Article
8. Clarke R, Halsey J, Lewington S, et al. Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: meta-analysis of 8 randomized trials involving 37 485 individuals. Arch Intern Med. 2010; 170:1622–1631. PMID:
20937919.
Article
9. Martí-Carvajal AJ, Solà I, Lathyris D, Dayer M. Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev. 2017; 8:CD006612. PMID:
28816346.
Article
10. Wang X, Chen Z, Tian W, et al. Plasma homocysteine levels and risk of congestive heart failure or cardiomyopathy: a Mendelian randomization study. Front Cardiovasc Med. 2023; 10:1030257. PMID:
36776266.
Article